{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:32:50Z","timestamp":1787754770854,"version":"build-2784847793"},"reference-count":133,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Endometrial carcinoma (EC) is the most frequent gynecological cancer, with an increasing incidence and mortality in recent times. The last decade has represented a true revolution with the development of the integrated histo-molecular classification of EC, which allows for the stratification of patients with morphologically indistinguishable disease into groups with different prognoses. Particularly, the POLE-mutated subgroup exhibits outstanding survival. Nevertheless, the indiscriminate application of molecular classification appears premature. Its prognostic significance has been proven mainly in endometrioid EC, the most common histotype, but it has yet to be convincingly confirmed in the other minor histotypes, which indeed account for a relevant proportion of EC mortality. Moreover, its daily use both requires a mindful pathologist who is able to correctly evaluate and unambiguously report immunohistochemical staining used as a surrogated diagnostic tool and is hampered by the unavailability of POLE mutation analysis. Further molecular characterization of ECs is needed to allow for the identification of better-tailored therapies in different settings, as well as the safe avoidance of surgery for fertility preservation. Hopefully, the numerous ongoing clinical trials in the adjuvant and metastatic settings of EC will likely produce evidence to refine the histo-molecular classification and therapeutic guidelines. Our review aims to retrace the origin and evolution of the molecular classification for EC, reveal its strengths and limitations, show clinical relevance, and uncover the desired future developments.<\/jats:p>","DOI":"10.3390\/cancers16132458","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T03:48:56Z","timestamp":1720151336000},"page":"2458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Unsolved Issues in the Integrated Histo-Molecular Classification of Endometrial Carcinoma and Therapeutic Implications"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-3821","authenticated-orcid":false,"given":"Elisabetta","family":"Kuhn","sequence":"first","affiliation":[{"name":"Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy"},{"name":"Pathology Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0709-536X","authenticated-orcid":false,"given":"Donatella","family":"Gambini","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation Sciences, Casa di Cura Igea, 20144 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letterio","family":"Runza","sequence":"additional","affiliation":[{"name":"Pathology Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy"},{"name":"Pathology Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Scarfone","sequence":"additional","affiliation":[{"name":"Gynecology Oncology Unit, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-7162","authenticated-orcid":false,"given":"Gaetano","family":"Bulfamante","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy"},{"name":"Human Pathology and Molecular Pathology, TOMA Advanced Biomedical Assays S.p.A., 21052 Busto Arsizio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0136-4271","authenticated-orcid":false,"given":"Ayse","family":"Ayhan","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"},{"name":"Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"djx030","DOI":"10.1093\/jnci\/djx030","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132014, Featuring Survival","volume":"109","author":"Jemal","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Scully, R.E. (1994). Histological Typing of Female Genital Tract Tumours, Springer. [2nd ed.]. International histological classification of tumours.","DOI":"10.1007\/978-3-642-85014-1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_5","unstructured":"World Health Organization (2020). Female Genital Tumours, World Health Organization. [5th ed.]. WHO Classification of Tumours Vol. 4."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13669-011-0004-1","article-title":"Ovarian Cancer Is an Imported Disease: Fact or Fiction?","volume":"1","author":"Kuhn","year":"2012","journal-title":"Curr. Obstet. Gynecol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/jclinpath-2017-204787","article-title":"Diagnostic immunohistochemistry in gynaecological neoplasia: A brief survey of the most common scenarios","volume":"71","author":"Kuhn","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Vermij, L., Horeweg, N., Leon-Castillo, A., Rutten, T.A., Mileshkin, L.R., Mackay, H.J., Leary, A., Powell, M.E., Singh, N., and Crosbie, E.J. (2020). HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. Cancers, 13.","DOI":"10.3390\/cancers13010044"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/PAS.0b013e31802ee494","article-title":"Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: Similar outcomes belie distinctive biologic differences","volume":"31","author":"Soslow","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","unstructured":"Poulsen, H.E., Taylor, C.W., and Sobin, L.H. (1975). Histological Typing of Female Genital Tract Tumours, World Health Organization. International Histological Classification of Tumours."},{"key":"ref_14","unstructured":"World Health Organization, Tavassoli, F.A., Devilee, P., and International Agency for Research on Cancer (2003). Pathology and Genetics of Tumours of the Breast and Female Genital Organs, IARC Press. World Health Organisation Classification of Tumours."},{"key":"ref_15","unstructured":"Kurman, R.J., International Agency for Research on Cancer, and World Health Organization (2014). WHO Classification of Tumours of Female Reproductive Organs, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/PAS.0000000000001473","article-title":"Endometrial Gastric-type Carcinoma: An Aggressive and Morphologically Heterogenous New Histotype Arising From Gastric Metaplasia of the Endometrium","volume":"44","author":"Wong","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/modpathol.3800950","article-title":"Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data","volume":"20","author":"Alkushi","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PGP.0b013e3181cd6552","article-title":"High-grade endometrial carcinoma: Serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes","volume":"29","author":"Alkushi","year":"2010","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2013.102","article-title":"Reproducibility of histological cell type in high-grade endometrial carcinoma","volume":"26","author":"Han","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/path.4056","article-title":"Use of mutation profiles to refine the classification of endometrial carcinomas","volume":"228","author":"McConechy","year":"2012","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/modpathol.2010.44","article-title":"Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations","volume":"23","author":"Catasus","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/PGP.0000000000000654","article-title":"Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens","volume":"39","author":"Plotkin","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ygyno.2014.02.012","article-title":"High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma","volume":"133","author":"Stelloo","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Gilvazquez","year":"2020","journal-title":"J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2014Evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: Clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2015.01.541","article-title":"Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas","volume":"137","author":"McConechy","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdw542","article-title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","volume":"28","author":"Stelloo","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2023.12.001","article-title":"Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy","volume":"42","author":"Adib","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility","volume":"38","author":"Ronnett","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/PAS.0000000000001220","article-title":"Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas","volume":"43","author":"Sari","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/his.13925","article-title":"Lynch syndrome screening in gynaecological cancers: Results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results","volume":"75","author":"Ryan","year":"2019","journal-title":"Histopathology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cncr.35030","article-title":"Characterization of mismatch-repair\/microsatellite instability-discordant endometrial cancers","volume":"130","author":"Riedinger","year":"2024","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.32074\/1591-951X-926","article-title":"Biomarker characterization in endometrial cancer in Europe: First survey data analysis from 69 pathological academic and hospital labs","volume":"116","author":"Santoro","year":"2024","journal-title":"Pathologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-019-12985-x","article-title":"Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma","volume":"10","author":"Gotoh","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijgo.13937","article-title":"Prognostic value of the TCGA molecular classification in uterine carcinosarcoma","volume":"158","author":"Travaglino","year":"2022","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/PAS.0000000000001560","article-title":"Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups","volume":"44","author":"Howitt","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/PAS.0000000000000873","article-title":"Undifferentiated and Dedifferentiated Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis","volume":"41","author":"Espinosa","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12967-023-04264-7","article-title":"Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: A retrospective national study from TMRG and GINECO network","volume":"21","author":"Nigon","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12365","DOI":"10.1002\/cam4.5937","article-title":"Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study","volume":"12","author":"Reijnen","year":"2023","journal-title":"Cancer Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cjp2.18","article-title":"In-depth molecular profiling of the biphasic components of uterine carcinosarcomas","volume":"1","author":"McConechy","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated Molecular Characterization of Uterine Carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Huvila, J., Jamieson, A., Pors, J., Hoang, L., Mirkovic, J., Cochrane, D., McAlpine, J.N., and Gilks, C.B. (2024). Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics. Int. J. Gynecol. Pathol., 10\u201397.","DOI":"10.1097\/PGP.0000000000001010"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/PAS.0000000000001353","article-title":"Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis","volume":"43","author":"Saijo","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/PAS.0000000000000166","article-title":"Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma","volume":"38","author":"Kuhn","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/00313020601159494","article-title":"Undifferentiated carcinoma of the endometrium: A review","volume":"39","author":"Silva","year":"2007","journal-title":"Pathology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2016.184","article-title":"Molecular genetic heterogeneity in undifferentiated endometrial carcinomas","volume":"29","author":"Biscuola","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PAS.0000000000000941","article-title":"Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch\/Sucrose Nonfermentable Complex Proteins","volume":"42","author":"Hoang","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pathol.2020.07.015","article-title":"Clinicopathological significance of multiple molecular features in undifferentiated and dedifferentiated endometrial carcinomas","volume":"53","author":"Zhang","year":"2021","journal-title":"Pathology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/PAS.0000000000000536","article-title":"Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases","volume":"40","author":"Meng","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/PAS.0000000000000640","article-title":"Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors with Different Clinicopathologic and Molecular Genetic Features","volume":"40","author":"Espinosa","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/PAS.0000000000001461","article-title":"Endometrial Carcinomas with a \u201cSerous\u201d Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations","volume":"44","author":"Conlon","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1097\/PAS.0000000000001970","article-title":"Molecular Analysis of HPV-independent Primary Endometrial Squamous Cell Carcinoma Reveals TP53 and CDKN2A Comutations: A Clinicopathologic Analysis with Re-evaluation of Diagnostic Criteria","volume":"46","author":"Hopkins","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100652","DOI":"10.1016\/j.gore.2020.100652","article-title":"Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin","volume":"34","author":"Lin","year":"2020","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/PAS.0000000000001401","article-title":"Mesonephric-like Carcinoma of the Endometrium: A Subset of Endometrial Carcinoma with an Aggressive Behavior","volume":"44","author":"Euscher","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2023.01.024","article-title":"Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study","volume":"170","author":"Zhang","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41379-022-01066-y","article-title":"Genomic landscape of endometrial carcinomas of no specific molecular profile","volume":"35","author":"Nguyen","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/PAS.0b013e318212782a","article-title":"Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma","volume":"35","author":"Guan","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"De Leo, A., de Biase, D., Lenzi, J., Barbero, G., Turchetti, D., Grillini, M., Ravegnini, G., Angelini, S., Zamagni, C., and Coluccelli, S. (2021). ARID1A and CTNNB1\/\u03b2-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification. Cancers, 13.","DOI":"10.3390\/cancers13050950"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1158\/1078-0432.CCR-17-0566","article-title":"Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma","volume":"23","author":"Depreeuw","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1158\/1078-0432.CCR-19-4088","article-title":"FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes","volume":"26","author":"Sengal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cjp2.82","article-title":"Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification","volume":"3","author":"Karnezis","year":"2017","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gonzalez-Bosquet, J., Weroha, S.J., Bakkum-Gamez, J.N., Weaver, A.L., McGree, M.E., Dowdy, S.C., Famuyide, A.O., Kipp, B.R., Halling, K.C., and Yadav, S. (2023). Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1105504"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ravegnini, G., De Leo, A., Coada, C., Gorini, F., de Biase, D., Ceccarelli, C., Dondi, G., Tesei, M., De Crescenzo, E., and Santini, D. (2021). Identification of miR-499a-5p as a Potential Novel Biomarker for Risk Stratification in Endometrial Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.757678"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100085","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2023.03.016","article-title":"Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification","volume":"186","author":"Perrone","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","article-title":"Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"34","author":"McMeekin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ygyno.2020.09.039","article-title":"Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening","volume":"159","author":"Carr","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Gambini, D., Ferrero, S., and Kuhn, E. (2022). Lynch Syndrome: From Carcinogenesis to Prevention Interventions. Cancers, 14.","DOI":"10.3390\/cancers14174102"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PGP.0000000000000674","article-title":"Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma","volume":"40","author":"Brett","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ruscelli, M., Maloberti, T., Corradini, A.G., Rosini, F., Querzoli, G., Grillini, M., Altimari, A., Gruppioni, E., Sanza, V., and Costantino, A. (2023). Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma. J. Pers. Med., 13.","DOI":"10.3390\/jpm13050723"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Santoro, A., Angelico, G., Travaglino, A., Inzani, F., Arciuolo, D., Valente, M., D\u2019Alessandris, N., Scaglione, G., Fiorentino, V., and Raffone, A. (2021). New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO\/ESTRO\/ESP Guidelines. Cancers, 13.","DOI":"10.3390\/cancers13112623"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1158\/1078-0432.CCR-18-0266","article-title":"Adjuvant Treatment for POLE Proofreading Domain\u2013Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues","volume":"24","author":"Rayner","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wu, Q., Zhang, N., and Xie, X. (2022). The clinicopathological characteristics of POLE-mutated\/ultramutated endometrial carcinoma and prognostic value of POLE status: A meta-analysis based on 49 articles incorporating 12,120 patients. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10267-2"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e19281","DOI":"10.1097\/MD.0000000000019281","article-title":"Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis","volume":"99","author":"He","year":"2020","journal-title":"Medicine"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Jumaah, A.S., Al-Haddad, H.S., McAllister, K.A., and Yasseen, A.A. (2022). The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263585"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: International randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"Horeweg","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"van Weelden, W.J., Massuger, L.F.A.G., Pijnenborg, J.M.A., and Romano, A. (2019). Enitec EP645 Anti-estrogen treatment in endometrial cancer: A systematic review. Front. Oncol., 9.","DOI":"10.1136\/ijgc-2019-ESGO.701"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1525-1438.2007.00897.x","article-title":"Hormone therapy in advanced and recurrent endometrial cancer: A systematic review","volume":"17","author":"Decruze","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1525-1438.2007.01094.x","article-title":"Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up","volume":"18","author":"Sorbe","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"45","DOI":"10.6004\/jadpro.2022.13.1.4","article-title":"Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer","volume":"13","author":"Halla","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ijgo.14969","article-title":"Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies","volume":"164","author":"Yang","year":"2024","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e390772","DOI":"10.1200\/EDBK_390772","article-title":"Antibody-Drug Conjugates in Gynecologic Cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"17588359231157633","DOI":"10.1177\/17588359231157633","article-title":"A rapidly evolving landscape: Immune checkpoint inhibitors in pretreated metastatic endometrial cancer","volume":"15","author":"Tinker","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ygyno.2021.04.016","article-title":"Bevacizumab in advanced endometrial cancer","volume":"161","author":"Rubinstein","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jnci\/djs345","article-title":"Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses","volume":"104","author":"Kuhn","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: Tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2\/Neu (NCT01367002): Updated Overall Survival Analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.annonc.2024.04.007","article-title":"MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy","volume":"35","author":"Pignata","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Assaraf","year":"2014","journal-title":"Drug Resist. Updat."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1535-7163.MCT-17-0930","article-title":"In vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers","volume":"17","author":"Altwerger","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1756-9966-30-106","article-title":"Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody","volume":"30","author":"Raji","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/IGC.0b013e318228f6da","article-title":"Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: Implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody","volume":"21","author":"Bignotti","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1200\/JCO.2020.38.15_suppl.6081","article-title":"Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): Results from a phase I\/II study","volume":"38","author":"Santin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41467-020-16416-0","article-title":"Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming","volume":"11","author":"Shen","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e000926","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Zanfagnin","year":"2020","journal-title":"ESMO Open"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_118","first-page":"CD012160","article-title":"PI3K\/AKT\/mTOR inhibitors for advanced or recurrent endometrial cancer","volume":"10","author":"Roncolato","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1200\/JCO.22.02906","article-title":"Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.20.03167","article-title":"Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1136\/ijgc-2023-004939","article-title":"PErsonalized TReatment for Endometrial Carcinoma (PETREC): Study design and methods of a prospective Finnish multicenter trial","volume":"33","author":"Loukovaara","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.3802\/jgo.2023.34.e37","article-title":"Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: A Chinese randomized phase III trial (PROBEAT)","volume":"34","author":"Li","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: The RAINBO clinical trial program","volume":"33","author":"Consortium","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.3802\/jgo.2021.32.e60","article-title":"Sentinel lymph Node mapping versus systematic pelvic lymphadenectomy on the prognosis for patients with intermediate-high-risk Endometrial Cancer confined to the uterus before surgery: Trial protocol for a non-inferiority randomized controlled trial (SNEC trial)","volume":"32","author":"Guan","year":"2021","journal-title":"J. Gynecol. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"hoac057","DOI":"10.1093\/hropen\/hoac057","article-title":"ESGO\/ESHRE\/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"2023","author":"Rodolakis","year":"2023","journal-title":"Hum. Reprod. Open"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1634\/theoncologist.2013-0445","article-title":"Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer","volume":"20","author":"Park","year":"2015","journal-title":"Oncologist"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/IGC.0000000000001164","article-title":"Fertility-Preserving Treatment in Young Women with Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis","volume":"28","author":"Fan","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Giampaolino, P., Cafasso, V., Boccia, D., Ascione, M., Mercorio, A., Viciglione, F., Palumbo, M., Serafino, P., Buonfantino, C., and De Angelis, M.C. (2022). Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review. BioMed Res. Int., 2022.","DOI":"10.1155\/2022\/4070368"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"154278","DOI":"10.1016\/j.prp.2022.154278","article-title":"Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia","volume":"241","author":"Zhang","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/1471-0528.14491","article-title":"Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: A consecutive case series","volume":"124","author":"Zakhour","year":"2017","journal-title":"BJOG"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2024.02.020","article-title":"Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer","volume":"185","author":"Agusti","year":"2024","journal-title":"Gynecol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/13\/2458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:10:17Z","timestamp":1760109017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/13\/2458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":133,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16132458"],"URL":"https:\/\/doi.org\/10.3390\/cancers16132458","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]}}}